By Mill Chart
Last update: May 26, 2025
EXELIXIS INC (NASDAQ:EXEL) stands out as a compelling candidate for investors following Louis Navellier’s growth-focused strategy. The company, which specializes in developing oncology treatments, meets multiple criteria outlined in Navellier’s "The Little Book That Makes You Rich," demonstrating strong earnings momentum, expanding margins, and robust cash flow. Below, we examine why EXEL fits this approach.
EXEL’s fundamental rating of 8/10 highlights its profitability, financial health, and growth potential. While its P/E ratio of 19.3 may seem elevated, it remains cheaper than 95% of its biotechnology peers. The company has no debt and maintains a healthy liquidity position, with a current ratio of 3.5.
For a deeper dive, review the full fundamental analysis report for EXEL.
Our Little Book That Makes You Rich screener identifies more stocks that fit this growth-focused strategy.
This is not investment advice. Always conduct your own research before making financial decisions.
42.39
-0.47 (-1.1%)
Find more stocks in the Stock Screener
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings growth, expanding margins, and solid cash flow, making it a standout for growth investors following Louis Navellier’s strategy.
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.
EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors.
EXELIXIS INC (NASDAQ:EXEL) meets Minervini’s Trend Template with strong technicals and high growth momentum, making it a standout in biotech. Review its full technical and fundamental strengths before considering an investment.